context
stringlengths 21
24.6k
| category
stringclasses 2
values | entity
stringlengths 1
12
| entity_type
stringclasses 5
values | query
stringlengths 97
3.31k
| answer
stringlengths 12
168
|
|---|---|---|---|---|---|
5 %, 5 %, and 6 % of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. | text | 5 | percentItemType | text: <entity> 5 </entity> <entity type> percentItemType </entity type> <context> 5 %, 5 %, and 6 % of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. </context> | us-gaap:FinancingReceivablePercentPastDue1 |
5 %, 5 %, and 6 % of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. | text | 6 | percentItemType | text: <entity> 6 </entity> <entity type> percentItemType </entity type> <context> 5 %, 5 %, and 6 % of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. </context> | us-gaap:FinancingReceivableNonaccrualPercentPastDue1 |
$ 12 million for the years ended December 31, 2024, 2023, and 2022, respectively, and is recognized within Other (income) expense – net i | text | 12 | monetaryItemType | text: <entity> 12 </entity> <entity type> monetaryItemType </entity type> <context> $ 12 million for the years ended December 31, 2024, 2023, and 2022, respectively, and is recognized within Other (income) expense – net i </context> | us-gaap:SalesTypeLeaseLeaseIncome |
On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. | text | 100 | percentItemType | text: <entity> 100 </entity> <entity type> percentItemType </entity type> <context> On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. </context> | us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired |
On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. | text | 259 | monetaryItemType | text: <entity> 259 </entity> <entity type> monetaryItemType </entity type> <context> On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. </context> | us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired |
On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. | text | 11 | monetaryItemType | text: <entity> 11 </entity> <entity type> monetaryItemType </entity type> <context> On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. </context> | us-gaap:CashAcquiredFromAcquisition |
On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. | text | 13 | monetaryItemType | text: <entity> 13 </entity> <entity type> monetaryItemType </entity type> <context> On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. </context> | us-gaap:BusinessCombinationContingentConsiderationLiability |
On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. | text | 283 | monetaryItemType | text: <entity> 283 </entity> <entity type> monetaryItemType </entity type> <context> On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. </context> | us-gaap:BusinessCombinationConsiderationTransferred1 |
On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. | text | 23 | monetaryItemType | text: <entity> 23 </entity> <entity type> monetaryItemType </entity type> <context> On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. </context> | us-gaap:BusinessCombinationContingentConsiderationLiability |
On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. | text | 194 | monetaryItemType | text: <entity> 194 </entity> <entity type> monetaryItemType </entity type> <context> On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. </context> | us-gaap:Goodwill |
On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. | text | 52 | monetaryItemType | text: <entity> 52 </entity> <entity type> monetaryItemType </entity type> <context> On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill |
On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. | text | 48 | monetaryItemType | text: <entity> 48 </entity> <entity type> monetaryItemType </entity type> <context> On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill |
On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. | text | 18 | monetaryItemType | text: <entity> 18 </entity> <entity type> monetaryItemType </entity type> <context> On April 1, 2024, the Company acquired 100 % of the stock of MIM Software Inc. (“MIM Software”) for approximately $ 259 million, net of cash acquired of $ 11 million, and potential contingent payments valued at $ 13 million pertaining to achievement of certain milestones, for a total preliminary purchase price of $ 283 million. The acquisition included up to $ 23 million of other contingent payments based on service requirements. The acquisition was funded with cash on hand. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 194 million, customer-related intangible assets of $ 52 million, developed technology intangible assets of $ 48 million, net deferred tax liabilities of $ 18 million, and other net assets of $ 7 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business, recorded within the Imaging segment, is non-deductible for tax purposes and is attributed to expected synergies and commercial benefits from use of the MIM Software technology in our existing GE HealthCare portfolio. MIM Software is a global provider of medical imaging analysis and artificial intelligence (“AI”) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities |
On February 17, 2023, the Company acquired 100 % of the stock of Caption Health, Inc. (“Caption Health”) for $ 127 million of upfront payment, $ 10 million of future holdback payment, and potential earn-out payments valued at $ 13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 94 million, intangible assets of $ 60 million, and deferred tax liabilities of $ 3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the AVS segment. Caption Health is an AI company whose technology expands access to AI-guided ultrasound screening for novice users. | text | 100 | percentItemType | text: <entity> 100 </entity> <entity type> percentItemType </entity type> <context> On February 17, 2023, the Company acquired 100 % of the stock of Caption Health, Inc. (“Caption Health”) for $ 127 million of upfront payment, $ 10 million of future holdback payment, and potential earn-out payments valued at $ 13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 94 million, intangible assets of $ 60 million, and deferred tax liabilities of $ 3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the AVS segment. Caption Health is an AI company whose technology expands access to AI-guided ultrasound screening for novice users. </context> | us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired |
On February 17, 2023, the Company acquired 100 % of the stock of Caption Health, Inc. (“Caption Health”) for $ 127 million of upfront payment, $ 10 million of future holdback payment, and potential earn-out payments valued at $ 13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 94 million, intangible assets of $ 60 million, and deferred tax liabilities of $ 3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the AVS segment. Caption Health is an AI company whose technology expands access to AI-guided ultrasound screening for novice users. | text | 127 | monetaryItemType | text: <entity> 127 </entity> <entity type> monetaryItemType </entity type> <context> On February 17, 2023, the Company acquired 100 % of the stock of Caption Health, Inc. (“Caption Health”) for $ 127 million of upfront payment, $ 10 million of future holdback payment, and potential earn-out payments valued at $ 13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 94 million, intangible assets of $ 60 million, and deferred tax liabilities of $ 3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the AVS segment. Caption Health is an AI company whose technology expands access to AI-guided ultrasound screening for novice users. </context> | us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired |
On February 17, 2023, the Company acquired 100 % of the stock of Caption Health, Inc. (“Caption Health”) for $ 127 million of upfront payment, $ 10 million of future holdback payment, and potential earn-out payments valued at $ 13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 94 million, intangible assets of $ 60 million, and deferred tax liabilities of $ 3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the AVS segment. Caption Health is an AI company whose technology expands access to AI-guided ultrasound screening for novice users. | text | 13 | monetaryItemType | text: <entity> 13 </entity> <entity type> monetaryItemType </entity type> <context> On February 17, 2023, the Company acquired 100 % of the stock of Caption Health, Inc. (“Caption Health”) for $ 127 million of upfront payment, $ 10 million of future holdback payment, and potential earn-out payments valued at $ 13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 94 million, intangible assets of $ 60 million, and deferred tax liabilities of $ 3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the AVS segment. Caption Health is an AI company whose technology expands access to AI-guided ultrasound screening for novice users. </context> | us-gaap:BusinessCombinationContingentConsiderationLiability |
On February 17, 2023, the Company acquired 100 % of the stock of Caption Health, Inc. (“Caption Health”) for $ 127 million of upfront payment, $ 10 million of future holdback payment, and potential earn-out payments valued at $ 13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 94 million, intangible assets of $ 60 million, and deferred tax liabilities of $ 3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the AVS segment. Caption Health is an AI company whose technology expands access to AI-guided ultrasound screening for novice users. | text | 94 | monetaryItemType | text: <entity> 94 </entity> <entity type> monetaryItemType </entity type> <context> On February 17, 2023, the Company acquired 100 % of the stock of Caption Health, Inc. (“Caption Health”) for $ 127 million of upfront payment, $ 10 million of future holdback payment, and potential earn-out payments valued at $ 13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 94 million, intangible assets of $ 60 million, and deferred tax liabilities of $ 3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the AVS segment. Caption Health is an AI company whose technology expands access to AI-guided ultrasound screening for novice users. </context> | us-gaap:Goodwill |
On February 17, 2023, the Company acquired 100 % of the stock of Caption Health, Inc. (“Caption Health”) for $ 127 million of upfront payment, $ 10 million of future holdback payment, and potential earn-out payments valued at $ 13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 94 million, intangible assets of $ 60 million, and deferred tax liabilities of $ 3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the AVS segment. Caption Health is an AI company whose technology expands access to AI-guided ultrasound screening for novice users. | text | 60 | monetaryItemType | text: <entity> 60 </entity> <entity type> monetaryItemType </entity type> <context> On February 17, 2023, the Company acquired 100 % of the stock of Caption Health, Inc. (“Caption Health”) for $ 127 million of upfront payment, $ 10 million of future holdback payment, and potential earn-out payments valued at $ 13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 94 million, intangible assets of $ 60 million, and deferred tax liabilities of $ 3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the AVS segment. Caption Health is an AI company whose technology expands access to AI-guided ultrasound screening for novice users. </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill |
On February 17, 2023, the Company acquired 100 % of the stock of Caption Health, Inc. (“Caption Health”) for $ 127 million of upfront payment, $ 10 million of future holdback payment, and potential earn-out payments valued at $ 13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 94 million, intangible assets of $ 60 million, and deferred tax liabilities of $ 3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the AVS segment. Caption Health is an AI company whose technology expands access to AI-guided ultrasound screening for novice users. | text | 3 | monetaryItemType | text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> On February 17, 2023, the Company acquired 100 % of the stock of Caption Health, Inc. (“Caption Health”) for $ 127 million of upfront payment, $ 10 million of future holdback payment, and potential earn-out payments valued at $ 13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $ 94 million, intangible assets of $ 60 million, and deferred tax liabilities of $ 3 million. The purchase price allocation for Caption Health was finalized in the first quarter of 2024 without material adjustments. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the AVS segment. Caption Health is an AI company whose technology expands access to AI-guided ultrasound screening for novice users. </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities |
The Company performs an impairment test of goodwill annually in the fourth quarter. In 2024, the Company performed quantitative testing for all reporting units that carried goodwill. The quantitative testing conducted concluded that no goodwill impairments existed. In 2023, a qualitative assessment was performed. Based on the results of the qualitative testing, the Company concluded that it was more likely than not that the fair value of each reporting unit exceeded its carrying value and no quantitative testing was required. | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> The Company performs an impairment test of goodwill annually in the fourth quarter. In 2024, the Company performed quantitative testing for all reporting units that carried goodwill. The quantitative testing conducted concluded that no goodwill impairments existed. In 2023, a qualitative assessment was performed. Based on the results of the qualitative testing, the Company concluded that it was more likely than not that the fair value of each reporting unit exceeded its carrying value and no quantitative testing was required. </context> | us-gaap:GoodwillImpairmentLoss |
, we recorded additions to acquired intangible assets subject to amortization of $ 117 million, primarily related to patents and technology and customer-related intangibles, with a weighted-average useful life of eight years . | text | 117 | monetaryItemType | text: <entity> 117 </entity> <entity type> monetaryItemType </entity type> <context> , we recorded additions to acquired intangible assets subject to amortization of $ 117 million, primarily related to patents and technology and customer-related intangibles, with a weighted-average useful life of eight years . </context> | us-gaap:FinitelivedIntangibleAssetsAcquired1 |
Amortization expense was $ 312 million, $ 362 million, and $ 405 million for the years ended December 31, 2024, 2023, and 2022, respectively. There were no material impairments of definite-lived intangible assets recognized in the years ended December 31, 2024, 2023, or 2022. | text | 312 | monetaryItemType | text: <entity> 312 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense was $ 312 million, $ 362 million, and $ 405 million for the years ended December 31, 2024, 2023, and 2022, respectively. There were no material impairments of definite-lived intangible assets recognized in the years ended December 31, 2024, 2023, or 2022. </context> | us-gaap:AmortizationOfIntangibleAssets |
Amortization expense was $ 312 million, $ 362 million, and $ 405 million for the years ended December 31, 2024, 2023, and 2022, respectively. There were no material impairments of definite-lived intangible assets recognized in the years ended December 31, 2024, 2023, or 2022. | text | 362 | monetaryItemType | text: <entity> 362 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense was $ 312 million, $ 362 million, and $ 405 million for the years ended December 31, 2024, 2023, and 2022, respectively. There were no material impairments of definite-lived intangible assets recognized in the years ended December 31, 2024, 2023, or 2022. </context> | us-gaap:AmortizationOfIntangibleAssets |
Amortization expense was $ 312 million, $ 362 million, and $ 405 million for the years ended December 31, 2024, 2023, and 2022, respectively. There were no material impairments of definite-lived intangible assets recognized in the years ended December 31, 2024, 2023, or 2022. | text | 405 | monetaryItemType | text: <entity> 405 </entity> <entity type> monetaryItemType </entity type> <context> Amortization expense was $ 312 million, $ 362 million, and $ 405 million for the years ended December 31, 2024, 2023, and 2022, respectively. There were no material impairments of definite-lived intangible assets recognized in the years ended December 31, 2024, 2023, or 2022. </context> | us-gaap:AmortizationOfIntangibleAssets |
The Company’s borrowings include $ 8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2025 through 2052 (collectively, the “Notes”). This reflects the $ 1,000 million aggregate principal amount of 4.800 % senior unsecured notes issued by the Company in the third quarter of 2024, and a repayment in the fourth quarter of 2024 of $ 1,000 million aggregate principal amount of 5.550 % senior unsecured notes. | text | 8250 | monetaryItemType | text: <entity> 8250 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s borrowings include $ 8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2025 through 2052 (collectively, the “Notes”). This reflects the $ 1,000 million aggregate principal amount of 4.800 % senior unsecured notes issued by the Company in the third quarter of 2024, and a repayment in the fourth quarter of 2024 of $ 1,000 million aggregate principal amount of 5.550 % senior unsecured notes. </context> | us-gaap:DebtInstrumentFaceAmount |
The Company’s borrowings include $ 8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2025 through 2052 (collectively, the “Notes”). This reflects the $ 1,000 million aggregate principal amount of 4.800 % senior unsecured notes issued by the Company in the third quarter of 2024, and a repayment in the fourth quarter of 2024 of $ 1,000 million aggregate principal amount of 5.550 % senior unsecured notes. | text | 1000 | monetaryItemType | text: <entity> 1000 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s borrowings include $ 8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2025 through 2052 (collectively, the “Notes”). This reflects the $ 1,000 million aggregate principal amount of 4.800 % senior unsecured notes issued by the Company in the third quarter of 2024, and a repayment in the fourth quarter of 2024 of $ 1,000 million aggregate principal amount of 5.550 % senior unsecured notes. </context> | us-gaap:DebtInstrumentFaceAmount |
The Company’s borrowings include $ 8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2025 through 2052 (collectively, the “Notes”). This reflects the $ 1,000 million aggregate principal amount of 4.800 % senior unsecured notes issued by the Company in the third quarter of 2024, and a repayment in the fourth quarter of 2024 of $ 1,000 million aggregate principal amount of 5.550 % senior unsecured notes. | text | 4.800 | percentItemType | text: <entity> 4.800 </entity> <entity type> percentItemType </entity type> <context> The Company’s borrowings include $ 8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2025 through 2052 (collectively, the “Notes”). This reflects the $ 1,000 million aggregate principal amount of 4.800 % senior unsecured notes issued by the Company in the third quarter of 2024, and a repayment in the fourth quarter of 2024 of $ 1,000 million aggregate principal amount of 5.550 % senior unsecured notes. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
The Company’s borrowings include $ 8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2025 through 2052 (collectively, the “Notes”). This reflects the $ 1,000 million aggregate principal amount of 4.800 % senior unsecured notes issued by the Company in the third quarter of 2024, and a repayment in the fourth quarter of 2024 of $ 1,000 million aggregate principal amount of 5.550 % senior unsecured notes. | text | 1000 | monetaryItemType | text: <entity> 1000 </entity> <entity type> monetaryItemType </entity type> <context> The Company’s borrowings include $ 8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2025 through 2052 (collectively, the “Notes”). This reflects the $ 1,000 million aggregate principal amount of 4.800 % senior unsecured notes issued by the Company in the third quarter of 2024, and a repayment in the fourth quarter of 2024 of $ 1,000 million aggregate principal amount of 5.550 % senior unsecured notes. </context> | us-gaap:RepaymentsOfLongTermDebt |
The Company’s borrowings include $ 8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2025 through 2052 (collectively, the “Notes”). This reflects the $ 1,000 million aggregate principal amount of 4.800 % senior unsecured notes issued by the Company in the third quarter of 2024, and a repayment in the fourth quarter of 2024 of $ 1,000 million aggregate principal amount of 5.550 % senior unsecured notes. | text | 5.550 | percentItemType | text: <entity> 5.550 </entity> <entity type> percentItemType </entity type> <context> The Company’s borrowings include $ 8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2025 through 2052 (collectively, the “Notes”). This reflects the $ 1,000 million aggregate principal amount of 4.800 % senior unsecured notes issued by the Company in the third quarter of 2024, and a repayment in the fourth quarter of 2024 of $ 1,000 million aggregate principal amount of 5.550 % senior unsecured notes. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
Interest payments on the Notes are due semi-annually until maturity. In the event of a change in control and a related downgrade of the ratings of the Notes below investment grade, the indenture governing the Notes requires that the Company make an offer to each holder of the Notes to repurchase all or any part of that holder’s notes at a repurchase price equal to 101 % of the aggregate principal amount of the Notes repurchased, plus any accrued and unpaid interest. The indenture also includes a limitation on liens incurred by the Company and its wholly owned U.S. subsidiaries. The indenture does not restrict the Company or its subsidiaries from incurring indebtedness, nor does it contain any financial covenants. All covenants are subject to a number of exceptions, limitations, and qualifications. Refer to the table below for further information about the Notes. | text | 101 | percentItemType | text: <entity> 101 </entity> <entity type> percentItemType </entity type> <context> Interest payments on the Notes are due semi-annually until maturity. In the event of a change in control and a related downgrade of the ratings of the Notes below investment grade, the indenture governing the Notes requires that the Company make an offer to each holder of the Notes to repurchase all or any part of that holder’s notes at a repurchase price equal to 101 % of the aggregate principal amount of the Notes repurchased, plus any accrued and unpaid interest. The indenture also includes a limitation on liens incurred by the Company and its wholly owned U.S. subsidiaries. The indenture does not restrict the Company or its subsidiaries from incurring indebtedness, nor does it contain any financial covenants. All covenants are subject to a number of exceptions, limitations, and qualifications. Refer to the table below for further information about the Notes. </context> | us-gaap:DebtInstrumentRedemptionPricePercentage |
a five-year senior unsecured revolving credit facility in an aggregate committed amount of $ 2,500 million, maturing on January 3, 2028; | text | 2500 | monetaryItemType | text: <entity> 2500 </entity> <entity type> monetaryItemType </entity type> <context> a five-year senior unsecured revolving credit facility in an aggregate committed amount of $ 2,500 million, maturing on January 3, 2028; </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $ 1,000 million, maturing on December 10, 2025; and | text | 1000 | monetaryItemType | text: <entity> 1000 </entity> <entity type> monetaryItemType </entity type> <context> a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $ 1,000 million, maturing on December 10, 2025; and </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
a three-year senior unsecured term loan credit facility in an aggregate principal amount of $ 2,000 million, maturing on January 2, 2026 (the “Term Loan Facility” and, together with the five-year revolving credit facility and the 364-day revolving credit facility, the “Credit Facilities”). | text | 2000 | monetaryItemType | text: <entity> 2000 </entity> <entity type> monetaryItemType </entity type> <context> a three-year senior unsecured term loan credit facility in an aggregate principal amount of $ 2,000 million, maturing on January 2, 2026 (the “Term Loan Facility” and, together with the five-year revolving credit facility and the 364-day revolving credit facility, the “Credit Facilities”). </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility, and there was $ 750 million and $ 1,150 million outstanding on the Term Loan Facility as of December 31, 2024 and 2023, respectively. In the first and fourth quarters of 2024, we repaid $ 150 million and $ 250 million, respectively, of the Term Loan Facility. In the fourth quarter of 2024, we entered into a new 364-day senior unsecured revolving credit facility to replace the 364-day senior unsecured revolving credit facility that matured in December 2024. | text | 750 | monetaryItemType | text: <entity> 750 </entity> <entity type> monetaryItemType </entity type> <context> There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility, and there was $ 750 million and $ 1,150 million outstanding on the Term Loan Facility as of December 31, 2024 and 2023, respectively. In the first and fourth quarters of 2024, we repaid $ 150 million and $ 250 million, respectively, of the Term Loan Facility. In the fourth quarter of 2024, we entered into a new 364-day senior unsecured revolving credit facility to replace the 364-day senior unsecured revolving credit facility that matured in December 2024. </context> | us-gaap:DebtInstrumentCarryingAmount |
There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility, and there was $ 750 million and $ 1,150 million outstanding on the Term Loan Facility as of December 31, 2024 and 2023, respectively. In the first and fourth quarters of 2024, we repaid $ 150 million and $ 250 million, respectively, of the Term Loan Facility. In the fourth quarter of 2024, we entered into a new 364-day senior unsecured revolving credit facility to replace the 364-day senior unsecured revolving credit facility that matured in December 2024. | text | 1150 | monetaryItemType | text: <entity> 1150 </entity> <entity type> monetaryItemType </entity type> <context> There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility, and there was $ 750 million and $ 1,150 million outstanding on the Term Loan Facility as of December 31, 2024 and 2023, respectively. In the first and fourth quarters of 2024, we repaid $ 150 million and $ 250 million, respectively, of the Term Loan Facility. In the fourth quarter of 2024, we entered into a new 364-day senior unsecured revolving credit facility to replace the 364-day senior unsecured revolving credit facility that matured in December 2024. </context> | us-gaap:DebtInstrumentCarryingAmount |
There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility, and there was $ 750 million and $ 1,150 million outstanding on the Term Loan Facility as of December 31, 2024 and 2023, respectively. In the first and fourth quarters of 2024, we repaid $ 150 million and $ 250 million, respectively, of the Term Loan Facility. In the fourth quarter of 2024, we entered into a new 364-day senior unsecured revolving credit facility to replace the 364-day senior unsecured revolving credit facility that matured in December 2024. | text | 150 | monetaryItemType | text: <entity> 150 </entity> <entity type> monetaryItemType </entity type> <context> There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility, and there was $ 750 million and $ 1,150 million outstanding on the Term Loan Facility as of December 31, 2024 and 2023, respectively. In the first and fourth quarters of 2024, we repaid $ 150 million and $ 250 million, respectively, of the Term Loan Facility. In the fourth quarter of 2024, we entered into a new 364-day senior unsecured revolving credit facility to replace the 364-day senior unsecured revolving credit facility that matured in December 2024. </context> | us-gaap:RepaymentsOfLongTermDebt |
There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility, and there was $ 750 million and $ 1,150 million outstanding on the Term Loan Facility as of December 31, 2024 and 2023, respectively. In the first and fourth quarters of 2024, we repaid $ 150 million and $ 250 million, respectively, of the Term Loan Facility. In the fourth quarter of 2024, we entered into a new 364-day senior unsecured revolving credit facility to replace the 364-day senior unsecured revolving credit facility that matured in December 2024. | text | 250 | monetaryItemType | text: <entity> 250 </entity> <entity type> monetaryItemType </entity type> <context> There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility, and there was $ 750 million and $ 1,150 million outstanding on the Term Loan Facility as of December 31, 2024 and 2023, respectively. In the first and fourth quarters of 2024, we repaid $ 150 million and $ 250 million, respectively, of the Term Loan Facility. In the fourth quarter of 2024, we entered into a new 364-day senior unsecured revolving credit facility to replace the 364-day senior unsecured revolving credit facility that matured in December 2024. </context> | us-gaap:RepaymentsOfLongTermDebt |
$ 1,500 million and $ 1,002 million, respectively, | text | 1500 | monetaryItemType | text: <entity> 1500 </entity> <entity type> monetaryItemType </entity type> <context> $ 1,500 million and $ 1,002 million, respectively, </context> | us-gaap:LongTermDebtCurrent |
$ 1,500 million and $ 1,002 million, respectively, | text | 1002 | monetaryItemType | text: <entity> 1002 </entity> <entity type> monetaryItemType </entity type> <context> $ 1,500 million and $ 1,002 million, respectively, </context> | us-gaap:LongTermDebtCurrent |
Interest expense associated with long-term debt was $ 580 million, $ 616 million, and $ 54 million for the years ended December 31, 2024, 2023, and 2022, respectively, and is included in Interest and other financial charges – net in the Consolidated and Combined Statements of Income. | text | 580 | monetaryItemType | text: <entity> 580 </entity> <entity type> monetaryItemType </entity type> <context> Interest expense associated with long-term debt was $ 580 million, $ 616 million, and $ 54 million for the years ended December 31, 2024, 2023, and 2022, respectively, and is included in Interest and other financial charges – net in the Consolidated and Combined Statements of Income. </context> | us-gaap:InterestExpenseLongTermDebt |
Interest expense associated with long-term debt was $ 580 million, $ 616 million, and $ 54 million for the years ended December 31, 2024, 2023, and 2022, respectively, and is included in Interest and other financial charges – net in the Consolidated and Combined Statements of Income. | text | 616 | monetaryItemType | text: <entity> 616 </entity> <entity type> monetaryItemType </entity type> <context> Interest expense associated with long-term debt was $ 580 million, $ 616 million, and $ 54 million for the years ended December 31, 2024, 2023, and 2022, respectively, and is included in Interest and other financial charges – net in the Consolidated and Combined Statements of Income. </context> | us-gaap:InterestExpenseLongTermDebt |
Interest expense associated with long-term debt was $ 580 million, $ 616 million, and $ 54 million for the years ended December 31, 2024, 2023, and 2022, respectively, and is included in Interest and other financial charges – net in the Consolidated and Combined Statements of Income. | text | 54 | monetaryItemType | text: <entity> 54 </entity> <entity type> monetaryItemType </entity type> <context> Interest expense associated with long-term debt was $ 580 million, $ 616 million, and $ 54 million for the years ended December 31, 2024, 2023, and 2022, respectively, and is included in Interest and other financial charges – net in the Consolidated and Combined Statements of Income. </context> | us-gaap:InterestExpenseLongTermDebt |
As of December 31, 2024 and 2023, the Company had bank guarantees and surety bonds of approximately $ 784 million and $ 751 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $ 25 million and $ 39 million of guarantees as of December 31, 2024 and 2023, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Consolidated Statements of Financial Position reflect a liability of $ 3 million and $ 4 million as of December 31, 2024 and 2023, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE. | text | 784 | monetaryItemType | text: <entity> 784 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company had bank guarantees and surety bonds of approximately $ 784 million and $ 751 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $ 25 million and $ 39 million of guarantees as of December 31, 2024 and 2023, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Consolidated Statements of Financial Position reflect a liability of $ 3 million and $ 4 million as of December 31, 2024 and 2023, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE. </context> | us-gaap:GuaranteeObligationsMaximumExposure |
As of December 31, 2024 and 2023, the Company had bank guarantees and surety bonds of approximately $ 784 million and $ 751 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $ 25 million and $ 39 million of guarantees as of December 31, 2024 and 2023, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Consolidated Statements of Financial Position reflect a liability of $ 3 million and $ 4 million as of December 31, 2024 and 2023, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE. | text | 751 | monetaryItemType | text: <entity> 751 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company had bank guarantees and surety bonds of approximately $ 784 million and $ 751 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $ 25 million and $ 39 million of guarantees as of December 31, 2024 and 2023, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Consolidated Statements of Financial Position reflect a liability of $ 3 million and $ 4 million as of December 31, 2024 and 2023, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE. </context> | us-gaap:GuaranteeObligationsMaximumExposure |
As of December 31, 2024 and 2023, the Company had bank guarantees and surety bonds of approximately $ 784 million and $ 751 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $ 25 million and $ 39 million of guarantees as of December 31, 2024 and 2023, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Consolidated Statements of Financial Position reflect a liability of $ 3 million and $ 4 million as of December 31, 2024 and 2023, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE. | text | 25 | monetaryItemType | text: <entity> 25 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company had bank guarantees and surety bonds of approximately $ 784 million and $ 751 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $ 25 million and $ 39 million of guarantees as of December 31, 2024 and 2023, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Consolidated Statements of Financial Position reflect a liability of $ 3 million and $ 4 million as of December 31, 2024 and 2023, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE. </context> | us-gaap:GuaranteeObligationsMaximumExposure |
As of December 31, 2024 and 2023, the Company had bank guarantees and surety bonds of approximately $ 784 million and $ 751 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $ 25 million and $ 39 million of guarantees as of December 31, 2024 and 2023, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Consolidated Statements of Financial Position reflect a liability of $ 3 million and $ 4 million as of December 31, 2024 and 2023, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE. | text | 39 | monetaryItemType | text: <entity> 39 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company had bank guarantees and surety bonds of approximately $ 784 million and $ 751 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $ 25 million and $ 39 million of guarantees as of December 31, 2024 and 2023, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Consolidated Statements of Financial Position reflect a liability of $ 3 million and $ 4 million as of December 31, 2024 and 2023, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE. </context> | us-gaap:GuaranteeObligationsMaximumExposure |
As of December 31, 2024 and 2023, the Company had bank guarantees and surety bonds of approximately $ 784 million and $ 751 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $ 25 million and $ 39 million of guarantees as of December 31, 2024 and 2023, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Consolidated Statements of Financial Position reflect a liability of $ 3 million and $ 4 million as of December 31, 2024 and 2023, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE. | text | 3 | monetaryItemType | text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company had bank guarantees and surety bonds of approximately $ 784 million and $ 751 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $ 25 million and $ 39 million of guarantees as of December 31, 2024 and 2023, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Consolidated Statements of Financial Position reflect a liability of $ 3 million and $ 4 million as of December 31, 2024 and 2023, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE. </context> | us-gaap:GuaranteeObligationsCurrentCarryingValue |
As of December 31, 2024 and 2023, the Company had bank guarantees and surety bonds of approximately $ 784 million and $ 751 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $ 25 million and $ 39 million of guarantees as of December 31, 2024 and 2023, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Consolidated Statements of Financial Position reflect a liability of $ 3 million and $ 4 million as of December 31, 2024 and 2023, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE. | text | 4 | monetaryItemType | text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company had bank guarantees and surety bonds of approximately $ 784 million and $ 751 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $ 25 million and $ 39 million of guarantees as of December 31, 2024 and 2023, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Consolidated Statements of Financial Position reflect a liability of $ 3 million and $ 4 million as of December 31, 2024 and 2023, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE. </context> | us-gaap:GuaranteeObligationsCurrentCarryingValue |
Expenses associated with our employees’ participation in the U.S. GE Pension Plan and certain U.S. retiree benefit plans, which represent the majority of related expense, were $ 73 million for the year ended December 31, 2022. Expenses associated with our employees’ participation in certain international pension plans were $ 11 million for the year ended December 31, 2022. | text | 73 | monetaryItemType | text: <entity> 73 </entity> <entity type> monetaryItemType </entity type> <context> Expenses associated with our employees’ participation in the U.S. GE Pension Plan and certain U.S. retiree benefit plans, which represent the majority of related expense, were $ 73 million for the year ended December 31, 2022. Expenses associated with our employees’ participation in certain international pension plans were $ 11 million for the year ended December 31, 2022. </context> | us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost |
Expenses associated with our employees’ participation in the U.S. GE Pension Plan and certain U.S. retiree benefit plans, which represent the majority of related expense, were $ 73 million for the year ended December 31, 2022. Expenses associated with our employees’ participation in certain international pension plans were $ 11 million for the year ended December 31, 2022. | text | 11 | monetaryItemType | text: <entity> 11 </entity> <entity type> monetaryItemType </entity type> <context> Expenses associated with our employees’ participation in the U.S. GE Pension Plan and certain U.S. retiree benefit plans, which represent the majority of related expense, were $ 73 million for the year ended December 31, 2022. Expenses associated with our employees’ participation in certain international pension plans were $ 11 million for the year ended December 31, 2022. </context> | us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost |
The U.S. Pension Plans are comprised of the obligations transferred to GE HealthCare from GE in connection with the Spin-Off and obligations that existed prior to the Spin-Off. The largest plans include the GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan, which provides supplementary benefits to higher-level, longer-service U.S. employees. The GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan have been closed to new participants since 2012. All remaining service accruals for the GE HealthCare Pension Plan were frozen effective December 31, 2024. Benefits for participants of the GE HealthCare Supplemental Pension Plan who became executives before 2011 were frozen effective January 1, 2021, and thereafter these employees accrue a benefit which is paid out in ten annual installments upon retirement. The GE HealthCare Pension Plan has a projected benefit obligation of $ 15,230 million, plan assets of $ 13,650 million, and is 90 % funded per U.S. GAAP as of December 31, 2024. The GE HealthCare Supplemental Pension plan has a projected benefit obligation of $ 1,886 million as of December 31, 2024, and the benefits are paid to eligible participants directly by the Company as described further in “Funding” below. | text | 15230 | monetaryItemType | text: <entity> 15230 </entity> <entity type> monetaryItemType </entity type> <context> The U.S. Pension Plans are comprised of the obligations transferred to GE HealthCare from GE in connection with the Spin-Off and obligations that existed prior to the Spin-Off. The largest plans include the GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan, which provides supplementary benefits to higher-level, longer-service U.S. employees. The GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan have been closed to new participants since 2012. All remaining service accruals for the GE HealthCare Pension Plan were frozen effective December 31, 2024. Benefits for participants of the GE HealthCare Supplemental Pension Plan who became executives before 2011 were frozen effective January 1, 2021, and thereafter these employees accrue a benefit which is paid out in ten annual installments upon retirement. The GE HealthCare Pension Plan has a projected benefit obligation of $ 15,230 million, plan assets of $ 13,650 million, and is 90 % funded per U.S. GAAP as of December 31, 2024. The GE HealthCare Supplemental Pension plan has a projected benefit obligation of $ 1,886 million as of December 31, 2024, and the benefits are paid to eligible participants directly by the Company as described further in “Funding” below. </context> | us-gaap:DefinedBenefitPlanBenefitObligation |
The U.S. Pension Plans are comprised of the obligations transferred to GE HealthCare from GE in connection with the Spin-Off and obligations that existed prior to the Spin-Off. The largest plans include the GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan, which provides supplementary benefits to higher-level, longer-service U.S. employees. The GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan have been closed to new participants since 2012. All remaining service accruals for the GE HealthCare Pension Plan were frozen effective December 31, 2024. Benefits for participants of the GE HealthCare Supplemental Pension Plan who became executives before 2011 were frozen effective January 1, 2021, and thereafter these employees accrue a benefit which is paid out in ten annual installments upon retirement. The GE HealthCare Pension Plan has a projected benefit obligation of $ 15,230 million, plan assets of $ 13,650 million, and is 90 % funded per U.S. GAAP as of December 31, 2024. The GE HealthCare Supplemental Pension plan has a projected benefit obligation of $ 1,886 million as of December 31, 2024, and the benefits are paid to eligible participants directly by the Company as described further in “Funding” below. | text | 13650 | monetaryItemType | text: <entity> 13650 </entity> <entity type> monetaryItemType </entity type> <context> The U.S. Pension Plans are comprised of the obligations transferred to GE HealthCare from GE in connection with the Spin-Off and obligations that existed prior to the Spin-Off. The largest plans include the GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan, which provides supplementary benefits to higher-level, longer-service U.S. employees. The GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan have been closed to new participants since 2012. All remaining service accruals for the GE HealthCare Pension Plan were frozen effective December 31, 2024. Benefits for participants of the GE HealthCare Supplemental Pension Plan who became executives before 2011 were frozen effective January 1, 2021, and thereafter these employees accrue a benefit which is paid out in ten annual installments upon retirement. The GE HealthCare Pension Plan has a projected benefit obligation of $ 15,230 million, plan assets of $ 13,650 million, and is 90 % funded per U.S. GAAP as of December 31, 2024. The GE HealthCare Supplemental Pension plan has a projected benefit obligation of $ 1,886 million as of December 31, 2024, and the benefits are paid to eligible participants directly by the Company as described further in “Funding” below. </context> | us-gaap:DefinedBenefitPlanFairValueOfPlanAssets |
The U.S. Pension Plans are comprised of the obligations transferred to GE HealthCare from GE in connection with the Spin-Off and obligations that existed prior to the Spin-Off. The largest plans include the GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan, which provides supplementary benefits to higher-level, longer-service U.S. employees. The GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan have been closed to new participants since 2012. All remaining service accruals for the GE HealthCare Pension Plan were frozen effective December 31, 2024. Benefits for participants of the GE HealthCare Supplemental Pension Plan who became executives before 2011 were frozen effective January 1, 2021, and thereafter these employees accrue a benefit which is paid out in ten annual installments upon retirement. The GE HealthCare Pension Plan has a projected benefit obligation of $ 15,230 million, plan assets of $ 13,650 million, and is 90 % funded per U.S. GAAP as of December 31, 2024. The GE HealthCare Supplemental Pension plan has a projected benefit obligation of $ 1,886 million as of December 31, 2024, and the benefits are paid to eligible participants directly by the Company as described further in “Funding” below. | text | 90 | percentItemType | text: <entity> 90 </entity> <entity type> percentItemType </entity type> <context> The U.S. Pension Plans are comprised of the obligations transferred to GE HealthCare from GE in connection with the Spin-Off and obligations that existed prior to the Spin-Off. The largest plans include the GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan, which provides supplementary benefits to higher-level, longer-service U.S. employees. The GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan have been closed to new participants since 2012. All remaining service accruals for the GE HealthCare Pension Plan were frozen effective December 31, 2024. Benefits for participants of the GE HealthCare Supplemental Pension Plan who became executives before 2011 were frozen effective January 1, 2021, and thereafter these employees accrue a benefit which is paid out in ten annual installments upon retirement. The GE HealthCare Pension Plan has a projected benefit obligation of $ 15,230 million, plan assets of $ 13,650 million, and is 90 % funded per U.S. GAAP as of December 31, 2024. The GE HealthCare Supplemental Pension plan has a projected benefit obligation of $ 1,886 million as of December 31, 2024, and the benefits are paid to eligible participants directly by the Company as described further in “Funding” below. </context> | us-gaap:DefinedBenefitPlanFundedPercentage |
The U.S. Pension Plans are comprised of the obligations transferred to GE HealthCare from GE in connection with the Spin-Off and obligations that existed prior to the Spin-Off. The largest plans include the GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan, which provides supplementary benefits to higher-level, longer-service U.S. employees. The GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan have been closed to new participants since 2012. All remaining service accruals for the GE HealthCare Pension Plan were frozen effective December 31, 2024. Benefits for participants of the GE HealthCare Supplemental Pension Plan who became executives before 2011 were frozen effective January 1, 2021, and thereafter these employees accrue a benefit which is paid out in ten annual installments upon retirement. The GE HealthCare Pension Plan has a projected benefit obligation of $ 15,230 million, plan assets of $ 13,650 million, and is 90 % funded per U.S. GAAP as of December 31, 2024. The GE HealthCare Supplemental Pension plan has a projected benefit obligation of $ 1,886 million as of December 31, 2024, and the benefits are paid to eligible participants directly by the Company as described further in “Funding” below. | text | 1886 | monetaryItemType | text: <entity> 1886 </entity> <entity type> monetaryItemType </entity type> <context> The U.S. Pension Plans are comprised of the obligations transferred to GE HealthCare from GE in connection with the Spin-Off and obligations that existed prior to the Spin-Off. The largest plans include the GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan, which provides supplementary benefits to higher-level, longer-service U.S. employees. The GE HealthCare Pension Plan and the GE HealthCare Supplemental Pension Plan have been closed to new participants since 2012. All remaining service accruals for the GE HealthCare Pension Plan were frozen effective December 31, 2024. Benefits for participants of the GE HealthCare Supplemental Pension Plan who became executives before 2011 were frozen effective January 1, 2021, and thereafter these employees accrue a benefit which is paid out in ten annual installments upon retirement. The GE HealthCare Pension Plan has a projected benefit obligation of $ 15,230 million, plan assets of $ 13,650 million, and is 90 % funded per U.S. GAAP as of December 31, 2024. The GE HealthCare Supplemental Pension plan has a projected benefit obligation of $ 1,886 million as of December 31, 2024, and the benefits are paid to eligible participants directly by the Company as described further in “Funding” below. </context> | us-gaap:DefinedBenefitPlanBenefitObligation |
The Company funds annually, at a minimum, the statutorily required minimum amount for our qualified plans. Non-qualified plans are unfunded and we pay benefits from our cash on hand. In 2025, the Company expects to make total cash contributions of approximately $ 327 million to these plans. | text | 327 | monetaryItemType | text: <entity> 327 </entity> <entity type> monetaryItemType </entity type> <context> The Company funds annually, at a minimum, the statutorily required minimum amount for our qualified plans. Non-qualified plans are unfunded and we pay benefits from our cash on hand. In 2025, the Company expects to make total cash contributions of approximately $ 327 million to these plans. </context> | us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear |
With respect to the retirement benefit balances included on our Consolidated Statement of Financial Position as of December 31, 2024, we estimate that we will amortize $ 119 million of net actuarial gain and $ 93 million of prior service credit from AOCI into Non-operating benefit (income) cost in the Consolidated Statement of Income during 2025. | text | 119 | monetaryItemType | text: <entity> 119 </entity> <entity type> monetaryItemType </entity type> <context> With respect to the retirement benefit balances included on our Consolidated Statement of Financial Position as of December 31, 2024, we estimate that we will amortize $ 119 million of net actuarial gain and $ 93 million of prior service credit from AOCI into Non-operating benefit (income) cost in the Consolidated Statement of Income during 2025. </context> | us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear |
With respect to the retirement benefit balances included on our Consolidated Statement of Financial Position as of December 31, 2024, we estimate that we will amortize $ 119 million of net actuarial gain and $ 93 million of prior service credit from AOCI into Non-operating benefit (income) cost in the Consolidated Statement of Income during 2025. | text | 93 | monetaryItemType | text: <entity> 93 </entity> <entity type> monetaryItemType </entity type> <context> With respect to the retirement benefit balances included on our Consolidated Statement of Financial Position as of December 31, 2024, we estimate that we will amortize $ 119 million of net actuarial gain and $ 93 million of prior service credit from AOCI into Non-operating benefit (income) cost in the Consolidated Statement of Income during 2025. </context> | us-gaap:DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear |
In the third quarter of 2023, management approved an amendment to the U.S. based GE HealthCare Pension Plan whereby the benefits for all remaining active employees were frozen effective December 31, 2024, and additional benefit enhancements were provided. As a result, we recognized a non-cash pre-tax curtailment loss of approximately $ 17 million as non-operating benefit costs and an increase to our pension liability of $ 23 million in 2023. As a result of the plan changes, we remeasured the plan assets and the projected benefit obligation. These changes collectively decreased AOCI by $ 305 million in the Consolidated Statement of Financial Position. | text | 17 | monetaryItemType | text: <entity> 17 </entity> <entity type> monetaryItemType </entity type> <context> In the third quarter of 2023, management approved an amendment to the U.S. based GE HealthCare Pension Plan whereby the benefits for all remaining active employees were frozen effective December 31, 2024, and additional benefit enhancements were provided. As a result, we recognized a non-cash pre-tax curtailment loss of approximately $ 17 million as non-operating benefit costs and an increase to our pension liability of $ 23 million in 2023. As a result of the plan changes, we remeasured the plan assets and the projected benefit obligation. These changes collectively decreased AOCI by $ 305 million in the Consolidated Statement of Financial Position. </context> | us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments |
In the third quarter of 2023, management approved an amendment to the U.S. based GE HealthCare Pension Plan whereby the benefits for all remaining active employees were frozen effective December 31, 2024, and additional benefit enhancements were provided. As a result, we recognized a non-cash pre-tax curtailment loss of approximately $ 17 million as non-operating benefit costs and an increase to our pension liability of $ 23 million in 2023. As a result of the plan changes, we remeasured the plan assets and the projected benefit obligation. These changes collectively decreased AOCI by $ 305 million in the Consolidated Statement of Financial Position. | text | 23 | monetaryItemType | text: <entity> 23 </entity> <entity type> monetaryItemType </entity type> <context> In the third quarter of 2023, management approved an amendment to the U.S. based GE HealthCare Pension Plan whereby the benefits for all remaining active employees were frozen effective December 31, 2024, and additional benefit enhancements were provided. As a result, we recognized a non-cash pre-tax curtailment loss of approximately $ 17 million as non-operating benefit costs and an increase to our pension liability of $ 23 million in 2023. As a result of the plan changes, we remeasured the plan assets and the projected benefit obligation. These changes collectively decreased AOCI by $ 305 million in the Consolidated Statement of Financial Position. </context> | us-gaap:DefinedBenefitPlanCurtailments |
In the third quarter of 2023, management approved an amendment to the U.S. based GE HealthCare Pension Plan whereby the benefits for all remaining active employees were frozen effective December 31, 2024, and additional benefit enhancements were provided. As a result, we recognized a non-cash pre-tax curtailment loss of approximately $ 17 million as non-operating benefit costs and an increase to our pension liability of $ 23 million in 2023. As a result of the plan changes, we remeasured the plan assets and the projected benefit obligation. These changes collectively decreased AOCI by $ 305 million in the Consolidated Statement of Financial Position. | text | 305 | monetaryItemType | text: <entity> 305 </entity> <entity type> monetaryItemType </entity type> <context> In the third quarter of 2023, management approved an amendment to the U.S. based GE HealthCare Pension Plan whereby the benefits for all remaining active employees were frozen effective December 31, 2024, and additional benefit enhancements were provided. As a result, we recognized a non-cash pre-tax curtailment loss of approximately $ 17 million as non-operating benefit costs and an increase to our pension liability of $ 23 million in 2023. As a result of the plan changes, we remeasured the plan assets and the projected benefit obligation. These changes collectively decreased AOCI by $ 305 million in the Consolidated Statement of Financial Position. </context> | us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax |
In the fourth quarter of 2023, management approved and paid a one-time lump sum payment for certain terminated employees in two plans who were vested in their benefits. These lump sum settlements reduce our future cash requirements. As a result of the partial settlement of the pension liability, we recognized a non-cash pre-tax settlement charge in 2023. The settlement charge of $ 61 million represents a pro rata portion of unrecognized net loss recorded in AOCI and is recorded in Non-operating benefit (income) costs in the Consolidated Statement of Income. | text | 61 | monetaryItemType | text: <entity> 61 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2023, management approved and paid a one-time lump sum payment for certain terminated employees in two plans who were vested in their benefits. These lump sum settlements reduce our future cash requirements. As a result of the partial settlement of the pension liability, we recognized a non-cash pre-tax settlement charge in 2023. The settlement charge of $ 61 million represents a pro rata portion of unrecognized net loss recorded in AOCI and is recorded in Non-operating benefit (income) costs in the Consolidated Statement of Income. </context> | us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 |
For the December 31, 2024 postretirement health care obligations remeasurement, the Company assumed a 8.0 % initial weighted average rate of increase in the per capita cost of the various covered health care benefits, which applies primarily to non-Medicare eligible participants. The trend rate was assumed to decrease gradually to an ultimate rate of 4.5 % in 2036 and remain at that level thereafter. | text | 8.0 | percentItemType | text: <entity> 8.0 </entity> <entity type> percentItemType </entity type> <context> For the December 31, 2024 postretirement health care obligations remeasurement, the Company assumed a 8.0 % initial weighted average rate of increase in the per capita cost of the various covered health care benefits, which applies primarily to non-Medicare eligible participants. The trend rate was assumed to decrease gradually to an ultimate rate of 4.5 % in 2036 and remain at that level thereafter. </context> | us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear |
For the December 31, 2024 postretirement health care obligations remeasurement, the Company assumed a 8.0 % initial weighted average rate of increase in the per capita cost of the various covered health care benefits, which applies primarily to non-Medicare eligible participants. The trend rate was assumed to decrease gradually to an ultimate rate of 4.5 % in 2036 and remain at that level thereafter. | text | 4.5 | percentItemType | text: <entity> 4.5 </entity> <entity type> percentItemType </entity type> <context> For the December 31, 2024 postretirement health care obligations remeasurement, the Company assumed a 8.0 % initial weighted average rate of increase in the per capita cost of the various covered health care benefits, which applies primarily to non-Medicare eligible participants. The trend rate was assumed to decrease gradually to an ultimate rate of 4.5 % in 2036 and remain at that level thereafter. </context> | us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1 |
As of December 31, 2024 and 2023, the fair value of plan assets that used significant unobservable inputs (Level 3) was $ 692 million and $ 626 million, respectively. These assets primarily relate to real estate and private equity investments. The changes to the balances of Level 3 plan assets during 2024 were not significant. During 2023, the balances of Level 3 plan assets increased from $ 61 million as of December 31, 2022 to $ 626 million as of December 31, 2023 primarily as a result of the transferred liabilities and assets to GE HealthCare on January 1, 2023. | text | 692 | monetaryItemType | text: <entity> 692 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the fair value of plan assets that used significant unobservable inputs (Level 3) was $ 692 million and $ 626 million, respectively. These assets primarily relate to real estate and private equity investments. The changes to the balances of Level 3 plan assets during 2024 were not significant. During 2023, the balances of Level 3 plan assets increased from $ 61 million as of December 31, 2022 to $ 626 million as of December 31, 2023 primarily as a result of the transferred liabilities and assets to GE HealthCare on January 1, 2023. </context> | us-gaap:DefinedBenefitPlanFairValueOfPlanAssets |
As of December 31, 2024 and 2023, the fair value of plan assets that used significant unobservable inputs (Level 3) was $ 692 million and $ 626 million, respectively. These assets primarily relate to real estate and private equity investments. The changes to the balances of Level 3 plan assets during 2024 were not significant. During 2023, the balances of Level 3 plan assets increased from $ 61 million as of December 31, 2022 to $ 626 million as of December 31, 2023 primarily as a result of the transferred liabilities and assets to GE HealthCare on January 1, 2023. | text | 626 | monetaryItemType | text: <entity> 626 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the fair value of plan assets that used significant unobservable inputs (Level 3) was $ 692 million and $ 626 million, respectively. These assets primarily relate to real estate and private equity investments. The changes to the balances of Level 3 plan assets during 2024 were not significant. During 2023, the balances of Level 3 plan assets increased from $ 61 million as of December 31, 2022 to $ 626 million as of December 31, 2023 primarily as a result of the transferred liabilities and assets to GE HealthCare on January 1, 2023. </context> | us-gaap:DefinedBenefitPlanFairValueOfPlanAssets |
As of December 31, 2024 and 2023, the fair value of plan assets that used significant unobservable inputs (Level 3) was $ 692 million and $ 626 million, respectively. These assets primarily relate to real estate and private equity investments. The changes to the balances of Level 3 plan assets during 2024 were not significant. During 2023, the balances of Level 3 plan assets increased from $ 61 million as of December 31, 2022 to $ 626 million as of December 31, 2023 primarily as a result of the transferred liabilities and assets to GE HealthCare on January 1, 2023. | text | 61 | monetaryItemType | text: <entity> 61 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the fair value of plan assets that used significant unobservable inputs (Level 3) was $ 692 million and $ 626 million, respectively. These assets primarily relate to real estate and private equity investments. The changes to the balances of Level 3 plan assets during 2024 were not significant. During 2023, the balances of Level 3 plan assets increased from $ 61 million as of December 31, 2022 to $ 626 million as of December 31, 2023 primarily as a result of the transferred liabilities and assets to GE HealthCare on January 1, 2023. </context> | us-gaap:DefinedBenefitPlanFairValueOfPlanAssets |
During the years ended December 31, 2023 and 2022, the Additions for tax positions of prior years line in the table above includes $ 134 million and $ 132 million, respectively, related to the Spin-Off. Also during the year ended December 31, 2023, a matter was closed with local tax authorities which resulted in the reversal of a net operating loss deferred tax asset and the related $ 183 million unrecognized tax benefit, which is included in the Reductions for tax positions of prior years line above. | text | 134 | monetaryItemType | text: <entity> 134 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2023 and 2022, the Additions for tax positions of prior years line in the table above includes $ 134 million and $ 132 million, respectively, related to the Spin-Off. Also during the year ended December 31, 2023, a matter was closed with local tax authorities which resulted in the reversal of a net operating loss deferred tax asset and the related $ 183 million unrecognized tax benefit, which is included in the Reductions for tax positions of prior years line above. </context> | us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions |
During the years ended December 31, 2023 and 2022, the Additions for tax positions of prior years line in the table above includes $ 134 million and $ 132 million, respectively, related to the Spin-Off. Also during the year ended December 31, 2023, a matter was closed with local tax authorities which resulted in the reversal of a net operating loss deferred tax asset and the related $ 183 million unrecognized tax benefit, which is included in the Reductions for tax positions of prior years line above. | text | 132 | monetaryItemType | text: <entity> 132 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2023 and 2022, the Additions for tax positions of prior years line in the table above includes $ 134 million and $ 132 million, respectively, related to the Spin-Off. Also during the year ended December 31, 2023, a matter was closed with local tax authorities which resulted in the reversal of a net operating loss deferred tax asset and the related $ 183 million unrecognized tax benefit, which is included in the Reductions for tax positions of prior years line above. </context> | us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions |
During the years ended December 31, 2023 and 2022, the Additions for tax positions of prior years line in the table above includes $ 134 million and $ 132 million, respectively, related to the Spin-Off. Also during the year ended December 31, 2023, a matter was closed with local tax authorities which resulted in the reversal of a net operating loss deferred tax asset and the related $ 183 million unrecognized tax benefit, which is included in the Reductions for tax positions of prior years line above. | text | 183 | monetaryItemType | text: <entity> 183 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2023 and 2022, the Additions for tax positions of prior years line in the table above includes $ 134 million and $ 132 million, respectively, related to the Spin-Off. Also during the year ended December 31, 2023, a matter was closed with local tax authorities which resulted in the reversal of a net operating loss deferred tax asset and the related $ 183 million unrecognized tax benefit, which is included in the Reductions for tax positions of prior years line above. </context> | us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions |
For the years ended December 31, 2024 and 2023, $ 13 million and $ 12 million, respectively, of interest expense on uncertain tax positions was recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. For the year ended December 31, 2022, $ 12 million of interest expense on uncertain tax positions was recorded in Interest and other financial charges – net in the Combined Statement of Income. For the years ended December 31, 2024 and 2023, $ 4 million and $ 6 million, respectively, of income tax penalties were recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. No accrual for penalties was made in the year ended December 31, 2022. | text | 13 | monetaryItemType | text: <entity> 13 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024 and 2023, $ 13 million and $ 12 million, respectively, of interest expense on uncertain tax positions was recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. For the year ended December 31, 2022, $ 12 million of interest expense on uncertain tax positions was recorded in Interest and other financial charges – net in the Combined Statement of Income. For the years ended December 31, 2024 and 2023, $ 4 million and $ 6 million, respectively, of income tax penalties were recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. No accrual for penalties was made in the year ended December 31, 2022. </context> | us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense |
For the years ended December 31, 2024 and 2023, $ 13 million and $ 12 million, respectively, of interest expense on uncertain tax positions was recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. For the year ended December 31, 2022, $ 12 million of interest expense on uncertain tax positions was recorded in Interest and other financial charges – net in the Combined Statement of Income. For the years ended December 31, 2024 and 2023, $ 4 million and $ 6 million, respectively, of income tax penalties were recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. No accrual for penalties was made in the year ended December 31, 2022. | text | 12 | monetaryItemType | text: <entity> 12 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024 and 2023, $ 13 million and $ 12 million, respectively, of interest expense on uncertain tax positions was recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. For the year ended December 31, 2022, $ 12 million of interest expense on uncertain tax positions was recorded in Interest and other financial charges – net in the Combined Statement of Income. For the years ended December 31, 2024 and 2023, $ 4 million and $ 6 million, respectively, of income tax penalties were recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. No accrual for penalties was made in the year ended December 31, 2022. </context> | us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense |
For the years ended December 31, 2024 and 2023, $ 13 million and $ 12 million, respectively, of interest expense on uncertain tax positions was recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. For the year ended December 31, 2022, $ 12 million of interest expense on uncertain tax positions was recorded in Interest and other financial charges – net in the Combined Statement of Income. For the years ended December 31, 2024 and 2023, $ 4 million and $ 6 million, respectively, of income tax penalties were recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. No accrual for penalties was made in the year ended December 31, 2022. | text | 4 | monetaryItemType | text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024 and 2023, $ 13 million and $ 12 million, respectively, of interest expense on uncertain tax positions was recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. For the year ended December 31, 2022, $ 12 million of interest expense on uncertain tax positions was recorded in Interest and other financial charges – net in the Combined Statement of Income. For the years ended December 31, 2024 and 2023, $ 4 million and $ 6 million, respectively, of income tax penalties were recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. No accrual for penalties was made in the year ended December 31, 2022. </context> | us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense |
For the years ended December 31, 2024 and 2023, $ 13 million and $ 12 million, respectively, of interest expense on uncertain tax positions was recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. For the year ended December 31, 2022, $ 12 million of interest expense on uncertain tax positions was recorded in Interest and other financial charges – net in the Combined Statement of Income. For the years ended December 31, 2024 and 2023, $ 4 million and $ 6 million, respectively, of income tax penalties were recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. No accrual for penalties was made in the year ended December 31, 2022. | text | 6 | monetaryItemType | text: <entity> 6 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024 and 2023, $ 13 million and $ 12 million, respectively, of interest expense on uncertain tax positions was recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. For the year ended December 31, 2022, $ 12 million of interest expense on uncertain tax positions was recorded in Interest and other financial charges – net in the Combined Statement of Income. For the years ended December 31, 2024 and 2023, $ 4 million and $ 6 million, respectively, of income tax penalties were recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. No accrual for penalties was made in the year ended December 31, 2022. </context> | us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense |
For the years ended December 31, 2024 and 2023, $ 13 million and $ 12 million, respectively, of interest expense on uncertain tax positions was recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. For the year ended December 31, 2022, $ 12 million of interest expense on uncertain tax positions was recorded in Interest and other financial charges – net in the Combined Statement of Income. For the years ended December 31, 2024 and 2023, $ 4 million and $ 6 million, respectively, of income tax penalties were recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. No accrual for penalties was made in the year ended December 31, 2022. | text | No | monetaryItemType | text: <entity> No </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024 and 2023, $ 13 million and $ 12 million, respectively, of interest expense on uncertain tax positions was recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. For the year ended December 31, 2022, $ 12 million of interest expense on uncertain tax positions was recorded in Interest and other financial charges – net in the Combined Statement of Income. For the years ended December 31, 2024 and 2023, $ 4 million and $ 6 million, respectively, of income tax penalties were recorded in Benefit (provision) for income taxes in the Consolidated Statements of Income. No accrual for penalties was made in the year ended December 31, 2022. </context> | us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense |
As a result of the Spin-Off, there was an increase in the valuation allowance of $ 269 million in 2023, which is included in the Foreign currency exchange and other line of the table above. For the year ended December 31, 2024, our valuation allowance decreased by $ 310 million, which included a release of a valuation allowance in France of $ 295 million reflected in the Provision for income taxes line. Based on our analysis of all positive and negative evidence during the year ended December 31, 2024, we concluded that it is more likely than not that France deferred tax assets will be realizable based on our profitability in France as a stand-alone company post Spin-Off and our expectation for the continued generation of prospective positive income in the jurisdiction. In making these judgments, we considered various business and structural factors as a stand-alone company, which support our conclusion of the realization of the deferred tax assets. | text | 310 | monetaryItemType | text: <entity> 310 </entity> <entity type> monetaryItemType </entity type> <context> As a result of the Spin-Off, there was an increase in the valuation allowance of $ 269 million in 2023, which is included in the Foreign currency exchange and other line of the table above. For the year ended December 31, 2024, our valuation allowance decreased by $ 310 million, which included a release of a valuation allowance in France of $ 295 million reflected in the Provision for income taxes line. Based on our analysis of all positive and negative evidence during the year ended December 31, 2024, we concluded that it is more likely than not that France deferred tax assets will be realizable based on our profitability in France as a stand-alone company post Spin-Off and our expectation for the continued generation of prospective positive income in the jurisdiction. In making these judgments, we considered various business and structural factors as a stand-alone company, which support our conclusion of the realization of the deferred tax assets. </context> | us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount |
As a result of the Spin-Off, there was an increase in the valuation allowance of $ 269 million in 2023, which is included in the Foreign currency exchange and other line of the table above. For the year ended December 31, 2024, our valuation allowance decreased by $ 310 million, which included a release of a valuation allowance in France of $ 295 million reflected in the Provision for income taxes line. Based on our analysis of all positive and negative evidence during the year ended December 31, 2024, we concluded that it is more likely than not that France deferred tax assets will be realizable based on our profitability in France as a stand-alone company post Spin-Off and our expectation for the continued generation of prospective positive income in the jurisdiction. In making these judgments, we considered various business and structural factors as a stand-alone company, which support our conclusion of the realization of the deferred tax assets. | text | 295 | monetaryItemType | text: <entity> 295 </entity> <entity type> monetaryItemType </entity type> <context> As a result of the Spin-Off, there was an increase in the valuation allowance of $ 269 million in 2023, which is included in the Foreign currency exchange and other line of the table above. For the year ended December 31, 2024, our valuation allowance decreased by $ 310 million, which included a release of a valuation allowance in France of $ 295 million reflected in the Provision for income taxes line. Based on our analysis of all positive and negative evidence during the year ended December 31, 2024, we concluded that it is more likely than not that France deferred tax assets will be realizable based on our profitability in France as a stand-alone company post Spin-Off and our expectation for the continued generation of prospective positive income in the jurisdiction. In making these judgments, we considered various business and structural factors as a stand-alone company, which support our conclusion of the realization of the deferred tax assets. </context> | us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount |
As of December 31, 2024, the Company had net operating loss carryforwards of $ 5,978 million primarily related to France, Ireland, Brazil, Germany, and the Netherlands, which can be carried forward indefinitely. The gross net operating loss carryforwards resulted in a deferred tax asset of $ 1,133 million as of December 31, 2024. This amount excludes accruals of $ 266 million for unrecognized tax benefits the Company has recorded related to the underlying tax positions which generated the net operating losses and expected impacts to U.S. foreign tax credits of $ 420 million. | text | 5978 | monetaryItemType | text: <entity> 5978 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had net operating loss carryforwards of $ 5,978 million primarily related to France, Ireland, Brazil, Germany, and the Netherlands, which can be carried forward indefinitely. The gross net operating loss carryforwards resulted in a deferred tax asset of $ 1,133 million as of December 31, 2024. This amount excludes accruals of $ 266 million for unrecognized tax benefits the Company has recorded related to the underlying tax positions which generated the net operating losses and expected impacts to U.S. foreign tax credits of $ 420 million. </context> | us-gaap:OperatingLossCarryforwards |
Post Spin-Off, the Company’s previously undistributed earnings of certain of our foreign subsidiaries are no longer indefinitely reinvested in non-U.S. businesses due to current U.S. funding needs. Therefore, in 2023, an incremental deferred tax liability of $ 21 million was recorded for withholding and other foreign taxes due upon future distribution of earnings. In addition, the Company is providing for withholding and other foreign taxes due upon future distribution of current period earnings. However, the Company generally considers instances of outside basis differences in foreign subsidiaries that would incur additional U.S. tax upon an unforeseen future reversal (e.g., capital gain distribution or disposition to an unrelated third party) of approximately $ 8 billion to be permanent in duration. Quantification of the deferred tax liability, if any, associated with indefinitely reinvested basis differences is not practicable. | text | 21 | monetaryItemType | text: <entity> 21 </entity> <entity type> monetaryItemType </entity type> <context> Post Spin-Off, the Company’s previously undistributed earnings of certain of our foreign subsidiaries are no longer indefinitely reinvested in non-U.S. businesses due to current U.S. funding needs. Therefore, in 2023, an incremental deferred tax liability of $ 21 million was recorded for withholding and other foreign taxes due upon future distribution of earnings. In addition, the Company is providing for withholding and other foreign taxes due upon future distribution of current period earnings. However, the Company generally considers instances of outside basis differences in foreign subsidiaries that would incur additional U.S. tax upon an unforeseen future reversal (e.g., capital gain distribution or disposition to an unrelated third party) of approximately $ 8 billion to be permanent in duration. Quantification of the deferred tax liability, if any, associated with indefinitely reinvested basis differences is not practicable. </context> | us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings |
Post Spin-Off, the Company’s previously undistributed earnings of certain of our foreign subsidiaries are no longer indefinitely reinvested in non-U.S. businesses due to current U.S. funding needs. Therefore, in 2023, an incremental deferred tax liability of $ 21 million was recorded for withholding and other foreign taxes due upon future distribution of earnings. In addition, the Company is providing for withholding and other foreign taxes due upon future distribution of current period earnings. However, the Company generally considers instances of outside basis differences in foreign subsidiaries that would incur additional U.S. tax upon an unforeseen future reversal (e.g., capital gain distribution or disposition to an unrelated third party) of approximately $ 8 billion to be permanent in duration. Quantification of the deferred tax liability, if any, associated with indefinitely reinvested basis differences is not practicable. | text | 8 | monetaryItemType | text: <entity> 8 </entity> <entity type> monetaryItemType </entity type> <context> Post Spin-Off, the Company’s previously undistributed earnings of certain of our foreign subsidiaries are no longer indefinitely reinvested in non-U.S. businesses due to current U.S. funding needs. Therefore, in 2023, an incremental deferred tax liability of $ 21 million was recorded for withholding and other foreign taxes due upon future distribution of earnings. In addition, the Company is providing for withholding and other foreign taxes due upon future distribution of current period earnings. However, the Company generally considers instances of outside basis differences in foreign subsidiaries that would incur additional U.S. tax upon an unforeseen future reversal (e.g., capital gain distribution or disposition to an unrelated third party) of approximately $ 8 billion to be permanent in duration. Quantification of the deferred tax liability, if any, associated with indefinitely reinvested basis differences is not practicable. </context> | us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries |
(3) Includes pre-tax impact to Pension and Other Postretirement Plans of $( 305 ) million for the pension plan amendment and related remeasurement of plan assets and benefit obligations. Refer to Note 10, | text | 305 | monetaryItemType | text: <entity> 305 </entity> <entity type> monetaryItemType </entity type> <context> (3) Includes pre-tax impact to Pension and Other Postretirement Plans of $( 305 ) million for the pension plan amendment and related remeasurement of plan assets and benefit obligations. Refer to Note 10, </context> | us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationBeforeTax |
flow hedges, changes in the fair value of designated hedging instruments are initially recorded as a component of AOCI and subsequently reclassified to earnings in the period in which the hedged transaction affects earnings and to the same financial statement line item impacted by the hedged transaction. As of December 31, 2024, we expect to reclassify $ 22 million of pre-tax net deferred gain associated with designated cash flow hedges to earnings in the next 12 months, contemporaneously with the impact on earnings of the related hedged transactions. | text | 22 | monetaryItemType | text: <entity> 22 </entity> <entity type> monetaryItemType </entity type> <context> flow hedges, changes in the fair value of designated hedging instruments are initially recorded as a component of AOCI and subsequently reclassified to earnings in the period in which the hedged transaction affects earnings and to the same financial statement line item impacted by the hedged transaction. As of December 31, 2024, we expect to reclassify $ 22 million of pre-tax net deferred gain associated with designated cash flow hedges to earnings in the next 12 months, contemporaneously with the impact on earnings of the related hedged transactions. </context> | us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths |
The cash flows associated with derivatives designated as net investment hedges are recorded in All other investing activities – net in the Consolidated and Combined Statements of Cash Flows. For the year ended December 31, 2024, All other investing activities – net includes a $ 94 million payment for the settlement of cross-currency swaps that were designated in net investment hedges. Cash flows from the periodic interest settlements on the cross-currency swaps are recorded in All other operating activities – net in the Consolidated and Combined Statements of Cash Flows. | text | 94 | monetaryItemType | text: <entity> 94 </entity> <entity type> monetaryItemType </entity type> <context> The cash flows associated with derivatives designated as net investment hedges are recorded in All other investing activities – net in the Consolidated and Combined Statements of Cash Flows. For the year ended December 31, 2024, All other investing activities – net includes a $ 94 million payment for the settlement of cross-currency swaps that were designated in net investment hedges. Cash flows from the periodic interest settlements on the cross-currency swaps are recorded in All other operating activities – net in the Consolidated and Combined Statements of Cash Flows. </context> | us-gaap:PaymentsForHedgeInvestingActivities |
The estimated fair value of borrowings as of December 31, 2024 and 2023 was $ 9,374 million and $ 9,959 million, respectively, compared to a carrying value (which only includes a reduction for unamortized debt issuance costs and discounts and cumulative basis adjustment) of $ 8,951 million and $ 9,442 million, respectively. The fair value of our borrowings includes accrued interest and is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 9, “Borrowings” and Note 18, “Supplemental Financial Information” for further information. | text | 9374 | monetaryItemType | text: <entity> 9374 </entity> <entity type> monetaryItemType </entity type> <context> The estimated fair value of borrowings as of December 31, 2024 and 2023 was $ 9,374 million and $ 9,959 million, respectively, compared to a carrying value (which only includes a reduction for unamortized debt issuance costs and discounts and cumulative basis adjustment) of $ 8,951 million and $ 9,442 million, respectively. The fair value of our borrowings includes accrued interest and is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 9, “Borrowings” and Note 18, “Supplemental Financial Information” for further information. </context> | us-gaap:LongTermDebtFairValue |
The estimated fair value of borrowings as of December 31, 2024 and 2023 was $ 9,374 million and $ 9,959 million, respectively, compared to a carrying value (which only includes a reduction for unamortized debt issuance costs and discounts and cumulative basis adjustment) of $ 8,951 million and $ 9,442 million, respectively. The fair value of our borrowings includes accrued interest and is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 9, “Borrowings” and Note 18, “Supplemental Financial Information” for further information. | text | 9959 | monetaryItemType | text: <entity> 9959 </entity> <entity type> monetaryItemType </entity type> <context> The estimated fair value of borrowings as of December 31, 2024 and 2023 was $ 9,374 million and $ 9,959 million, respectively, compared to a carrying value (which only includes a reduction for unamortized debt issuance costs and discounts and cumulative basis adjustment) of $ 8,951 million and $ 9,442 million, respectively. The fair value of our borrowings includes accrued interest and is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 9, “Borrowings” and Note 18, “Supplemental Financial Information” for further information. </context> | us-gaap:LongTermDebtFairValue |
The estimated fair value of borrowings as of December 31, 2024 and 2023 was $ 9,374 million and $ 9,959 million, respectively, compared to a carrying value (which only includes a reduction for unamortized debt issuance costs and discounts and cumulative basis adjustment) of $ 8,951 million and $ 9,442 million, respectively. The fair value of our borrowings includes accrued interest and is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 9, “Borrowings” and Note 18, “Supplemental Financial Information” for further information. | text | 8951 | monetaryItemType | text: <entity> 8951 </entity> <entity type> monetaryItemType </entity type> <context> The estimated fair value of borrowings as of December 31, 2024 and 2023 was $ 9,374 million and $ 9,959 million, respectively, compared to a carrying value (which only includes a reduction for unamortized debt issuance costs and discounts and cumulative basis adjustment) of $ 8,951 million and $ 9,442 million, respectively. The fair value of our borrowings includes accrued interest and is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 9, “Borrowings” and Note 18, “Supplemental Financial Information” for further information. </context> | us-gaap:LongTermDebtFairValue |
The estimated fair value of borrowings as of December 31, 2024 and 2023 was $ 9,374 million and $ 9,959 million, respectively, compared to a carrying value (which only includes a reduction for unamortized debt issuance costs and discounts and cumulative basis adjustment) of $ 8,951 million and $ 9,442 million, respectively. The fair value of our borrowings includes accrued interest and is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 9, “Borrowings” and Note 18, “Supplemental Financial Information” for further information. | text | 9442 | monetaryItemType | text: <entity> 9442 </entity> <entity type> monetaryItemType </entity type> <context> The estimated fair value of borrowings as of December 31, 2024 and 2023 was $ 9,374 million and $ 9,959 million, respectively, compared to a carrying value (which only includes a reduction for unamortized debt issuance costs and discounts and cumulative basis adjustment) of $ 8,951 million and $ 9,442 million, respectively. The fair value of our borrowings includes accrued interest and is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 9, “Borrowings” and Note 18, “Supplemental Financial Information” for further information. </context> | us-gaap:LongTermDebtFairValue |
Following the Spin-Off, which was completed pursuant to the Separation and Distribution Agreement, the Company had remaining performance guarantees on behalf of GE. Under the Separation and Distribution Agreement, GE was obligated to use reasonable best efforts to replace the Company as the guarantor or terminate all such performance guarantees. Until such termination or replacement, in the event of non-fulfillment of contractual obligations by the relevant obligors, the Company could have been obligated to make payments under the applicable instruments for which GE was obligated to reimburse and indemnify the Company. As of December 31, 2023, the Company’s maximum aggregate exposure, subject to GE reimbursement, was approximately $ 114 million. In the second quarter of 2024, these remaining performance guarantees were all terminated or replaced. | text | 114 | monetaryItemType | text: <entity> 114 </entity> <entity type> monetaryItemType </entity type> <context> Following the Spin-Off, which was completed pursuant to the Separation and Distribution Agreement, the Company had remaining performance guarantees on behalf of GE. Under the Separation and Distribution Agreement, GE was obligated to use reasonable best efforts to replace the Company as the guarantor or terminate all such performance guarantees. Until such termination or replacement, in the event of non-fulfillment of contractual obligations by the relevant obligors, the Company could have been obligated to make payments under the applicable instruments for which GE was obligated to reimburse and indemnify the Company. As of December 31, 2023, the Company’s maximum aggregate exposure, subject to GE reimbursement, was approximately $ 114 million. In the second quarter of 2024, these remaining performance guarantees were all terminated or replaced. </context> | us-gaap:GuaranteeObligationsMaximumExposure |
Our operations, like operations of other companies engaged in similar businesses, involve the use, disposal, and cleanup of substances regulated under environmental protection laws and nuclear decommissioning regulations. We have obligations for ongoing and future environmental remediation activities. Liabilities for environmental remediation and nuclear decommissioning exclude possible insurance recoveries. Due to uncertainties or changes regarding the status of laws, regulations, technology, and information related to individual sites and lawsuits, it is reasonably possible that our exposure will exceed amounts accrued, and amounts not currently reasonably estimable and/or probable may need to be accrued in future periods. Our environmental remediation liabilities, which are measured on an undiscounted basis, were $ 16 million and $ 19 million as of December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. | text | 16 | monetaryItemType | text: <entity> 16 </entity> <entity type> monetaryItemType </entity type> <context> Our operations, like operations of other companies engaged in similar businesses, involve the use, disposal, and cleanup of substances regulated under environmental protection laws and nuclear decommissioning regulations. We have obligations for ongoing and future environmental remediation activities. Liabilities for environmental remediation and nuclear decommissioning exclude possible insurance recoveries. Due to uncertainties or changes regarding the status of laws, regulations, technology, and information related to individual sites and lawsuits, it is reasonably possible that our exposure will exceed amounts accrued, and amounts not currently reasonably estimable and/or probable may need to be accrued in future periods. Our environmental remediation liabilities, which are measured on an undiscounted basis, were $ 16 million and $ 19 million as of December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. </context> | us-gaap:AccruedEnvironmentalLossContingenciesCurrent |
Our operations, like operations of other companies engaged in similar businesses, involve the use, disposal, and cleanup of substances regulated under environmental protection laws and nuclear decommissioning regulations. We have obligations for ongoing and future environmental remediation activities. Liabilities for environmental remediation and nuclear decommissioning exclude possible insurance recoveries. Due to uncertainties or changes regarding the status of laws, regulations, technology, and information related to individual sites and lawsuits, it is reasonably possible that our exposure will exceed amounts accrued, and amounts not currently reasonably estimable and/or probable may need to be accrued in future periods. Our environmental remediation liabilities, which are measured on an undiscounted basis, were $ 16 million and $ 19 million as of December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. | text | 19 | monetaryItemType | text: <entity> 19 </entity> <entity type> monetaryItemType </entity type> <context> Our operations, like operations of other companies engaged in similar businesses, involve the use, disposal, and cleanup of substances regulated under environmental protection laws and nuclear decommissioning regulations. We have obligations for ongoing and future environmental remediation activities. Liabilities for environmental remediation and nuclear decommissioning exclude possible insurance recoveries. Due to uncertainties or changes regarding the status of laws, regulations, technology, and information related to individual sites and lawsuits, it is reasonably possible that our exposure will exceed amounts accrued, and amounts not currently reasonably estimable and/or probable may need to be accrued in future periods. Our environmental remediation liabilities, which are measured on an undiscounted basis, were $ 16 million and $ 19 million as of December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. </context> | us-gaap:AccruedEnvironmentalLossContingenciesCurrent |
We record asset retirement obligations, which primarily relate to nuclear decommissioning, associated with the retirement of tangible long-lived assets as a liability in the period in which the obligation is incurred and its fair value can be reasonably estimated. The liability is measured at the present value of the obligation when incurred and is adjusted in subsequent periods. Corresponding asset retirement costs are generally capitalized as part of the carrying value of the related long-lived assets and depreciated over the assets’ useful lives. Our asset retirement obligations were $ 292 million and $ 267 million at December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. | text | 292 | monetaryItemType | text: <entity> 292 </entity> <entity type> monetaryItemType </entity type> <context> We record asset retirement obligations, which primarily relate to nuclear decommissioning, associated with the retirement of tangible long-lived assets as a liability in the period in which the obligation is incurred and its fair value can be reasonably estimated. The liability is measured at the present value of the obligation when incurred and is adjusted in subsequent periods. Corresponding asset retirement costs are generally capitalized as part of the carrying value of the related long-lived assets and depreciated over the assets’ useful lives. Our asset retirement obligations were $ 292 million and $ 267 million at December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. </context> | us-gaap:AssetRetirementObligation |
We record asset retirement obligations, which primarily relate to nuclear decommissioning, associated with the retirement of tangible long-lived assets as a liability in the period in which the obligation is incurred and its fair value can be reasonably estimated. The liability is measured at the present value of the obligation when incurred and is adjusted in subsequent periods. Corresponding asset retirement costs are generally capitalized as part of the carrying value of the related long-lived assets and depreciated over the assets’ useful lives. Our asset retirement obligations were $ 292 million and $ 267 million at December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. | text | 267 | monetaryItemType | text: <entity> 267 </entity> <entity type> monetaryItemType </entity type> <context> We record asset retirement obligations, which primarily relate to nuclear decommissioning, associated with the retirement of tangible long-lived assets as a liability in the period in which the obligation is incurred and its fair value can be reasonably estimated. The liability is measured at the present value of the obligation when incurred and is adjusted in subsequent periods. Corresponding asset retirement costs are generally capitalized as part of the carrying value of the related long-lived assets and depreciated over the assets’ useful lives. Our asset retirement obligations were $ 292 million and $ 267 million at December 31, 2024 and 2023, respectively, and are recognized within All other current liabilities and All other non-current liabilities in the Consolidated Statements of Financial Position. </context> | us-gaap:AssetRetirementObligation |
These restructuring initiatives are expected to result in additional expenses of approximately $ 36 million, to be incurred primarily over the next 12 months, substantially related to employee-related termination benefits and asset write-downs. Restructuring expenses (gains) are recognized within Cost of products, Cost of services, or SG&A, as appropriate, in the Consolidated and Combined Statements of Income. | text | 36 | monetaryItemType | text: <entity> 36 </entity> <entity type> monetaryItemType </entity type> <context> These restructuring initiatives are expected to result in additional expenses of approximately $ 36 million, to be incurred primarily over the next 12 months, substantially related to employee-related termination benefits and asset write-downs. Restructuring expenses (gains) are recognized within Cost of products, Cost of services, or SG&A, as appropriate, in the Consolidated and Combined Statements of Income. </context> | us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 |
We grant stock options, restricted stock units (“RSUs”), and performance share units (“PSUs”) to employees under the 2023 Long-Term Incentive Plan (“LTIP”). The Talent, Culture, and Compensation Committee of the Board of Directors approves grants under the LTIP. Under the LTIP, we are authorized to issue up to approximately 41 million shares. We record compensation expense for awards expected to vest over the vesting period. We estimate forfeitures based on experience and adjust expense to reflect actual forfeitures. When options are exercised, RSUs vest, and PSUs are earned, we issue shares from authorized unissued common stock. | text | 41 | sharesItemType | text: <entity> 41 </entity> <entity type> sharesItemType </entity type> <context> We grant stock options, restricted stock units (“RSUs”), and performance share units (“PSUs”) to employees under the 2023 Long-Term Incentive Plan (“LTIP”). The Talent, Culture, and Compensation Committee of the Board of Directors approves grants under the LTIP. Under the LTIP, we are authorized to issue up to approximately 41 million shares. We record compensation expense for awards expected to vest over the vesting period. We estimate forfeitures based on experience and adjust expense to reflect actual forfeitures. When options are exercised, RSUs vest, and PSUs are earned, we issue shares from authorized unissued common stock. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized |
Unrecognized compensation expense was $ 146 million as of December 31, 2024 and is expected to be recognized over a weighted-average period of approximately 1.8 years. | text | 146 | monetaryItemType | text: <entity> 146 </entity> <entity type> monetaryItemType </entity type> <context> Unrecognized compensation expense was $ 146 million as of December 31, 2024 and is expected to be recognized over a weighted-average period of approximately 1.8 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
On January 3, 2023, there were approximately 454 million shares of GE HealthCare common stock outstanding, including the interest in our outstanding shares of common stock retained by GE following the Distribution. The computation of basic and diluted earnings per common share for the year ended December 31, 2022 was calculated using this same number of common shares outstanding since no GE HealthCare equity awards were outstanding as of the Distribution Date. | text | 454 | sharesItemType | text: <entity> 454 </entity> <entity type> sharesItemType </entity type> <context> On January 3, 2023, there were approximately 454 million shares of GE HealthCare common stock outstanding, including the interest in our outstanding shares of common stock retained by GE following the Distribution. The computation of basic and diluted earnings per common share for the year ended December 31, 2022 was calculated using this same number of common shares outstanding since no GE HealthCare equity awards were outstanding as of the Distribution Date. </context> | us-gaap:CommonStockSharesOutstanding |
Depreciation related to Property, plant, and equipment – net, exclusive of ROU operating lease assets, was $ 268 million, $ 248 million, and $ 228 million for the years ended December 31, 2024, 2023, and 2022, respectively. | text | 268 | monetaryItemType | text: <entity> 268 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation related to Property, plant, and equipment – net, exclusive of ROU operating lease assets, was $ 268 million, $ 248 million, and $ 228 million for the years ended December 31, 2024, 2023, and 2022, respectively. </context> | us-gaap:Depreciation |
Depreciation related to Property, plant, and equipment – net, exclusive of ROU operating lease assets, was $ 268 million, $ 248 million, and $ 228 million for the years ended December 31, 2024, 2023, and 2022, respectively. | text | 248 | monetaryItemType | text: <entity> 248 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation related to Property, plant, and equipment – net, exclusive of ROU operating lease assets, was $ 268 million, $ 248 million, and $ 228 million for the years ended December 31, 2024, 2023, and 2022, respectively. </context> | us-gaap:Depreciation |
Depreciation related to Property, plant, and equipment – net, exclusive of ROU operating lease assets, was $ 268 million, $ 248 million, and $ 228 million for the years ended December 31, 2024, 2023, and 2022, respectively. | text | 228 | monetaryItemType | text: <entity> 228 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation related to Property, plant, and equipment – net, exclusive of ROU operating lease assets, was $ 268 million, $ 248 million, and $ 228 million for the years ended December 31, 2024, 2023, and 2022, respectively. </context> | us-gaap:Depreciation |
(2) In the first quarter of 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The redemption amount of $ 211 million was paid in the second quarter of 2023. | text | 211 | monetaryItemType | text: <entity> 211 </entity> <entity type> monetaryItemType </entity type> <context> (2) In the first quarter of 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The redemption amount of $ 211 million was paid in the second quarter of 2023. </context> | us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest |
As discussed in Note 10, “Postretirement Benefit Plans”, employees of the Company participated in pension, benefit, and contribution plans that were sponsored by GE. The Company was charged $ 207 million for the year ended December 31, 2022 related to employee participation in these plans. In connection with the Spin-Off, a portion of the plans were transferred to the Company. | text | 207 | monetaryItemType | text: <entity> 207 </entity> <entity type> monetaryItemType </entity type> <context> As discussed in Note 10, “Postretirement Benefit Plans”, employees of the Company participated in pension, benefit, and contribution plans that were sponsored by GE. The Company was charged $ 207 million for the year ended December 31, 2022 related to employee participation in these plans. In connection with the Spin-Off, a portion of the plans were transferred to the Company. </context> | us-gaap:RelatedPartyTransactionAmountsOfTransaction |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.